Evotec receives $8.4m CARB-X funding
Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1166 entries already.
Entries by Thomas Gabrielczyk
BioNTech and Fosun Pharma kick off Chinese COVID-19 trials
/in News/by Thomas GabrielczykBioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec partners with Secarna to develop LNA drugs
/in News/by Thomas GabrielczykEvotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
EC secures 300 million doses of COVID-19 vaccine
/in News/by Thomas GabrielczykThe European Commission has reserved 300 million doses from Sanofi SA/GSK plcs adjuvanted recombinant COVID-19 vaccine.
Roche’s IL-6 receptor blocker fails in Phase III
/in News/by Thomas GabrielczykRoche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Enthera Pharmaceuticals Srl raises 28m in Series A financing
/in News/by Thomas GabrielczykItalian start-up Enthera Pharmaceuticals has raised 28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Polyphor AG bags CHF19.3 in equity financing
/in News/by Thomas GabrielczykSwiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
COVID-19: Siemens assay outperforms antibody tests from competitors
/in News/by Thomas GabrielczykIn a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.
AMR: Big Pharma sets up US$1bn Fund
/in News/by Thomas GabrielczykAfter leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial […]
VarmX bags 32m in Series B round
/in News/by Thomas GabrielczykLeiden-based coagulant developer VarmX NV has closed a 32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.